GLP-1 Peptides for Weight Loss in 2026: Semaglutide, Tirzepatide, Retatrutide, and Survodutide Compared

The GLP-1 receptor agonist landscape has evolved from single-receptor targeting (GLP-1 only) through dual agonism (GLP-1/GIP) to triple agonism (GLP-1/GIP/glucagon), each step delivering incrementally greater weight-loss outcomes in clinical trials. In 2026, researchers and clinicians have four well-characterised compounds to consider: semaglutide, tirzepatide, retatrutide, and survodutide. This comparison examines their mechanistic profiles, clinical efficacy data, tolerability, and the research design implications of each.

GLP-1 Receptor Agonism: The Common Foundation

All four compounds share GLP-1 receptor activity as their foundational mechanism. GLP-1 receptor agonism reduces body weight through:

• Hypothalamic appetite suppression via arcuate nucleus signalling
• Delayed gastric emptying (reduced meal absorption rate)
• Improved insulin secretion (glucose-dependent)
• Glucagon suppression (reducing hepatic glucose output)

The incremental weight loss gains across generations reflect the addition of complementary receptor targets layered on this GLP-1 foundation.

Semaglutide: The GLP-1 Benchmark

Semaglutide is a GLP-1 receptor agonist with ~7-day half-life enabling once-weekly subcutaneous dosing. The STEP trial programme established it as the weight-loss benchmark: at 2.4 mg/week, subjects achieved an average 14.9% body weight reduction at 68 weeks in STEP 1. It is FDA-approved for obesity management (Wegovy) and type 2 diabetes (Ozempic). Cardiovascular outcome data (SELECT trial) confirms significant cardiovascular risk reduction — a key differentiator for clinical application beyond weight loss alone.

Tirzepatide: GLP-1 + GIP Dual Agonism

Tirzepatide adds GIP (glucose-dependent insulinotropic polypeptide) receptor co-agonism. GIP receptor activation complements GLP-1 effects through improved insulin sensitivity, enhanced adipose tissue lipid metabolism, and potentially reduced GI side effects compared to pure GLP-1 agonism. SURMOUNT-1 trial data at 15 mg/week showed 20.9% mean weight reduction at 72 weeks — a 40% relative improvement over semaglutide. FDA approval for obesity (Zepbound) and type 2 diabetes (Mounjaro) followed.

Retatrutide: Triple Agonism (GLP-1/GIP/Glucagon)

Retatrutide adds glucagon receptor co-agonism to the GLP-1/GIP profile. Glucagon receptor activation increases energy expenditure (hepatic fat oxidation, thermogenesis) and drives visceral fat mobilisation — mechanisms not present in semaglutide or tirzepatide. Phase 2 NEJM 2023 data demonstrated up to 24.2% mean weight reduction at 48 weeks at 12 mg/week — the highest published weight-loss efficacy for any injectable anti-obesity compound to date. Phase 3 trials are ongoing.

Survodutide: GLP-1 + Glucagon (No GIP)

Survodutide pairs GLP-1 and glucagon receptor agonism without GIP — a distinct dual-agonist profile. Its glucagon component drives hepatic fat oxidation and energy expenditure, making it particularly relevant for NASH/NAFLD research. Phase 2 trials demonstrated significant visceral fat reduction and weight loss, with dedicated NASH trial data emerging as a differentiating endpoint versus tirzepatide (which has minimal liver disease data).

Side Effect Profile Comparison

All four compounds share a GLP-1 class GI side-effect profile (nausea, vomiting, diarrhoea, constipation) that is dose-dependent and most pronounced during titration. Key tolerability differences:

• Semaglutide: Nausea ~40%, vomiting ~20% at 2.4 mg. Established long-term tolerability profile from large trials.
• Tirzepatide: Comparable GI profile; some data suggest slightly better tolerance than semaglutide due to GIP modulation.
• Retatrutide: GI effects somewhat more pronounced at high doses due to glucagon component; slow titration protocol essential.
• Survodutide: Similar GI profile; glucagon component may increase nausea vs pure GLP-1 approaches at equivalent doses.

Research Design Considerations

For researchers designing comparative or mechanistic studies:

• Cardiovascular endpoints: Semaglutide has established cardiovascular outcome data (SELECT); others require dedicated CVOT trials.
• Liver disease endpoints: Survodutide and retatrutide show more potential for NASH research than tirzepatide.
• Dose-response studies: Retatrutide's triple mechanism creates more variables for dose-response design.
• Washout periods: All four have ~5–7 day half-lives; 4–5 half-lives (~4–5 weeks) required for full washout.

Frequently Asked Questions

Which GLP-1 peptide produces the most weight loss?

Based on Phase 2 trial data, retatrutide (triple agonist) shows the highest published efficacy at ~24% mean weight reduction. Tirzepatide follows at ~21%, semaglutide at ~15%. Survodutide data is more limited but shows comparable efficacy to tirzepatide.

Can these compounds be used in combination?

Combining GLP-1 receptor agonists from the same class is not established in research practice and would create additive GI side effects. Combinations with mechanistically distinct compounds (e.g., cagrilintide, which is amylin-based) are an active research area.

What is the key advantage of semaglutide over newer compounds?

Established cardiovascular outcome data (SELECT trial showing 20% relative cardiovascular risk reduction) and the longest post-approval safety record remain semaglutide's primary advantages over the newer triple-agonist compounds.

References

• Wilding JPH, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384, 989–1002.
• Jastreboff AM, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387, 205–216.
• Jastreboff AM, et al. (2023). Triple–Hormone-Receptor Agonist Retatrutide for Obesity. New England Journal of Medicine, 389, 514–526.
• Lincoff AM, et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine, 389, 2221–2232.